Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The benefits and risks of alemtuzumab in multiple sclerosis.
Clustering of autoimmune diseases in patients with rosacea.
Antibodies as Mediators of Brain Pathology.
Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS.
Prevalence of multiple sclerosis in Brazil: A systematic review.
Segmented corpus callosum diffusivity correlates with the Expanded Disability Status Scale score in the early stages of relapsing-remitting multiple sclerosis.
Screening, Synthesis, and In Vitro Evaluation of Vinyl Sulfones as Inhibitors of Complement-Dependent Cytotoxicity in Neuromyelitis Optica.
DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis.
Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
Switching therapies in MS: what are the options?
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.
[The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis.]
Expression of Lymphatic Markers in the Adult Rat Spinal Cord.
Acute transverse myelitis in childhood: A single centre experience from North India.
Sex and gender issues in multiple sclerosis.
Transverse myelitis due to Staphylococcus aureus may occur without contiguous spread.
Treatment of Neurological Autoimmune Diseases with Immunoglobulins: First Insights from the Prospective SIGNS Registry.
Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models.
Optimal design of clinical trials with biologics using dose-time-response models.
Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
[Characteristics of coping strategies in patients with multiple sclerosis(review)].
The immune response in the CNS in Theiler's virus induced demyelinating disease switches from an early adaptive response to a chronic innate-like response.
Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes.
Intracortical Posterior Cingulate Myelin Content Relates to Error Processing: Results from T1- and T2-Weighted MRI Myelin Mapping and Electrophysiology in Healthy Adults.
Could antiretroviral drugs be effective in multiple sclerosis? A case report.
Pages
« first
‹ previous
…
452
453
454
455
456
457
458
459
460
…
next ›
last »